Company Background
NCI/NIH scientists established Oncogene Science, Inc. (OSI) in 1983 as a research and development organization focused on cancer and oncogenes. In 1991, OSI acquired Applied bioTechnology of Cambridge MA, which focused on the development and introduction of state-of-the-art tests for research-use-only (RUO) applications. It also focused on state-of-the-art diagnostic assays for IVD applications.
In 1995, OSI sold its Research Products business to CN BioSciences in order to focus resources and efforts within its biopharmaceuticals and diagnostics core competencies. Presently, CN BioSciences operates this business as Oncogene Research Products, and continues to sell antibodies and probes to the research community.
In 1997, Oncogene Science, Inc. changed its name to OSI Pharmaceuticals, Inc. (OSIP), and through a series of corporate partnerships, evolved Oncogene Science Diagnostics, Inc. (OSDI) into a wholly owned subsidiary of OSIP. On December 1, 1999, OSIP sold OSDI to the diagnostics business group of Bayer Corporation. Bayer Corporation is the U.S. holdings of Bayer AG headquartered in Leverkusen, Germany. Effective December 1, 1999, Oncogene Science Diagnostics assumed the trade name Oncogene Science. Then in January 2007, the Oncogene Science ELISA business operation became a part of newly formed Siemens Healthcare Diagnostics as part of the Bayer Healthcare Diagnostics acquisition by Siemens Medical Solutions.
To better serve the strategic focus of Oncogene Science, Siemens Healthcare Diagnostics sold in November 2010 the Oncogene Science business assets to WILEX Inc., a wholly owned US subsidiary of WILEX AG. WILEX AG is a biopharmaceutical company based in Munich, Germany which develops drugs with a low side effect profile and targeted treatment of different types of cancer as well as diagnostic agents for specific detection of tumors. WILEX Inc. licensed patent rights and took over the fully equipped, state-of-the-art laboratory facilities in Cambridge, MA. The licensed IP portfolio includes the only FDA cleared Serum HER-2/neu ELISA kit, CA IX patents covering CA IX ELISA and IHC products, as well as a uPA diagnostics patent family, which is complementary to the WILEX uPA and CAIX therapeutic and diagnostic IP portfolio.
